这些试验可能会改变严重肝病的治疗方法

IF 58.7 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Nature Medicine Pub Date : 2025-05-07 DOI:10.1038/d41591-025-00030-y

引用次数: 0

摘要

经过多年的错误开始，代谢功能障碍相关的脂肪性肝炎终于看到了治疗上的突破——从第一个批准的药物到逆转肝硬化的候选药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The trials that could transform treatment for serious liver disease

After years of false starts, metabolic dysfunction-associated steatohepatitis is finally seeing therapeutic breakthroughs — from the first approved drug to candidates that reverse cirrhosis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Medicine 医学-生化与分子生物学

CiteScore

100.90

自引率

0.70%

发文量

525

审稿时长

1 months

期刊介绍： Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors. Nature Medicine consider all types of clinical research, including: -Case-reports and small case series -Clinical trials, whether phase 1, 2, 3 or 4 -Observational studies -Meta-analyses -Biomarker studies -Public and global health studies Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.